Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06948331 · ClinicalTrials.gov registry record · Phase 2
RADA16 for Aquablation Day Case
A Phase 2 study, sponsored by NYU Langone Health.
- Not yet
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT06948331 is a Phase 2 study that has not yet begun recruiting, run by NYU Langone Health. The registered enrollment target is 25 participants.
The verdict
NCT06948331, a Phase 2 study, has not yet begun recruiting, sponsored by NYU Langone Health.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a pilot proof of concept single-arm study using PuraStat following Aquablation procedure to assess reduction of hematuria to allow for same day discharge. The primary objective is to assess how PuraStat affects post-operative hematuria following Aquablation. The secondary objective is to assess the number of patients discharged on the same day based on the hematuria criteria (Grade 0 and Grade I).
Interventions
- DEVICE PuraStat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06948331
The ClinicalTrials.gov registry entry for NCT06948331 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PuraStat is the first listed.
NCT06948331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06948331 about?
NCT06948331 is a clinical study titled "RADA16 for Aquablation Day Case". This is a pilot proof of concept single-arm study using PuraStat following Aquablation procedure to assess reduction of hematuria to allow for same day discharge. The primary objective is to assess how PuraStat affects post-operative hematuria following Aquablation. The secondary objective is to a...
What is the current status of trial NCT06948331?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2026-04-01. Estimated completion is 2026-08-01.
What interventions are being tested in trial NCT06948331?
The interventions under investigation include: PuraStat (DEVICE).
Who is sponsoring clinical trial NCT06948331?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.